FROM 01 Jun, Aussies with metastatic hormone-sensitive prostate cancer (mHSPC) will have access to Erlyand (apalutamide) through the PBS.
Erlyand is a non-chemo treatment option and the first of its kind to be listed on the PBS for mHSPC.
The listing is expected to benefit around 3,000 people each year, and means that eligible patients will pay only a maximum of $30 per script, or $7.30 with a concession card.
Without subsidy, it would cost patients more than $40,000 per year of treatment.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 May 23
